Dianthus Therapeutics, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): diluted EPS of -$0.81. It usually reports 12–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
-47
-26.9%
|
-0.81
+16.5%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-50
-58.8%
|
-0.90
-2.3%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-41
-38.4%
|
-0.85
-3.7%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
|
-64
-126.6%
|
-1.43
-78.4%
|
|
Oct 16, 2025
16 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
|
-37
-46.0%
|
-0.97
-31.1%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
|
-32
-79.6%
|
-0.88
-72.5%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1
|
-30
-114.7%
|
-0.82
-51.9%
|
|
Mar 11, 2025
70 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-28
-169.2%
|
-0.80
-12.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1690585
- Former names
- Magenta Therapeutics, Inc. (until Sep 8, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.